Financial Advisor to Infraredx, Inc. on its Sale to Nipro Corporation
LSH Partners’ professionals, while employed at Loeb Partners Corporation, advised Infraredx, Inc. (“Infraredx”), an intravascular imaging company committed to advancing the diagnosis and management of coronary artery disease globally, on its sale to Nipro Corporation (TYO:8086) (“Nipro”).
“By teaming up with one of the leading global medical equipment manufacturing companies in the world, Infraredx is able to leverage Nipro’s global network and vast resources to enhance its presence and impact a larger audience locally as well globally,” said Jason Bottiglieri, President and CEO of Infraredx. “We are pleased to combine our strengths to meet the demands of the marketplace and continue to deliver to the medical community cardiovascular imaging systems that hold the potential to revolutionize the management of cardiovascular disease.”
Harnessing 30 years of research into the association between heart attacks and lipid-core plaques, Infraredx has been committed to the design, manufacturing, and distribution of technologies that address the needs of practitioners and improve outcomes in the treatment of patients with coronary artery disease. With ongoing investment in several landmark global clinical trials, Infraredx’s mission, to enable cardiologists to predict heart attacks and prevent them, will continue.